Liyanage P. Perera, Ph.D.

Liyanage P. Perera, Ph.D.

  • Center for Cancer Research
  • National Cancer Institute
Lymphoid Malignancies Branch


Dr. Perera received his Ph.D. from the F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD in 1990 and joined the Laboratory of Clinical Investigation, NIAID in 1992 as a senior staff fellow. In 1997, he moved to the Metabolism Branch of NCI (now the Lymphoid Malignancies Branch) as a staff scientist and currently leads a translational research program. His research focuses on immunotherapeutic approaches including the generation of engineered T cells with chimeric antigen receptors (CAR) and targeted combinatorial drug regimens as therapeutic modalities for the treatment of cancer, infectious diseases, and autoimmune disorders. He is an inventor with two US patents (No. 5,747,272 and No.8,663,622), a recipient of several Federal Technology Transfer awards, and an NIH merit award.

Areas of Expertise



Selected Publications

Tofacitinib, a janus kinase inhibitor demonstrates efficacy in an IL-15 transgenic mouse model that recapitulates pathologic manifestations of celiac disease

Yokoyama S, Perera PY, Waldmann TA, Hiroi T, Perera LP.
J. Clin. Immunol.. 33: 586-94, 2013. [ Journal Article ]

The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use

Perera PY, Lichy JH, Waldmann TA, Perera LP.
Microbes Infect.. 14: 247-61, 2012. [ Journal Article ]

Malaria infections do not compromise vaccine-induced immunity against tuberculosis in mice

Parra M, Derrick SC, Yang A, Tian J, Kolibab K, Oakley M, Perera LP, Jacobs WR, Kumar S, Morris SL.
PLoS ONE. 6: e28164, 2011. [ Journal Article ]

IL-15 adjuvanted multivalent vaccinia-based universal influenza vaccine requires CD4+ T cells for heterosubtypic protection

Valkenburg SA, Li OT, Mak PW, Mok CK, Nicholls JM, Guan Y, Waldmann TA, Peiris JS, Perera LP, Poon LL.
Proc. Natl. Acad. Sci. U.S.A.. 111: 5676-81, 2014. [ Journal Article ]

Protective-antigen (PA) based anthrax vaccines confer protection against inhalation anthrax by precluding the establishment of a systemic infection

Merkel TJ, Perera PY, Lee GM, Verma A, Hiroi T, Yokote H, Waldmann TA, Perera LP.
Hum Vaccin Immunother. 9: 1841-8, 2013. [ Journal Article ]